Patent ID: 9074253
Filing Date: 2015-07-07
Classification: A61P,C12Q

Abstract:
1. A method of theranostic classification of a breast cancer tumor, the method comprising: determining an expression level of FOXC1 in a breast cancer tumor sample, wherein the expression level of FOXC1 is determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), using forward and reverse cDNA primers having the cDNA sequences of SEQ ID NO: 6 and SEQ ID NO: 7, respectively; and classifying the breast cancer tumor sample as a theranostic basal-like breast cancer subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the breast cancer tumor sample is determined to have a high expression level of FOXC1, wherein the high expression level of FOXC1 is above a 90th percentile level of FOXC1 expression levels for a dataset of breast cancer tumors, the dataset comprising all known breast cancer subtypes.